Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC) — Stella

Recruiting

Back to PASC Post Acute Sequelae of COVID-19 trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(2 sites)

United States

UC Davis EXPLORER Molecular Imaging Center, Sacramento, California

University of California San Francisco, San Francisco, California

Key details

Phase

Very early testing

Sponsor

University of California, Davis

Collaborators

National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco

Enrollment target

~51 participants

Started

December 2025

Primary completion

December 2028

Age range

18 Years and older

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov